Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro

References

• Joki T, Carroll RS, Dunn IF, Zhang J, Abe T, Black PM. Assessment of alterations in gene expression in recurrent malignant glioma after radiotherapy using complementary deoxyribonucleic acid microarrays. Neurosurgery 2001;48:195–201; Discussion 201–2.
   PubMedGoogle Scholar
• Yarden Y, Sliwkowsky MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–37
   PubMed Web of Science ®Google Scholar
• Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50: 8017–22
   PubMed Web of Science ®Google Scholar
• Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 2004; 108: 135–42
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053–63
   PubMed Web of Science ®Google Scholar
• Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for Gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 109–15
   PubMed Web of Science ®Google Scholar
• Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184–8
   PubMed Web of Science ®Google Scholar
• Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant glioma. Cancer Res 2003; 63: 7443–50
   PubMed Web of Science ®Google Scholar
• Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, et al. Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. Eur J Nucl Med Mol Imaging 2003; 30: 1348–56
   PubMedGoogle Scholar
• Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004; 10: 3216–24
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22: 133–42
   PubMed Web of Science ®Google Scholar
• Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett 2003; 202: 43–51
   PubMed Web of Science ®Google Scholar
• Fan Z, Baselgam J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637–42
   PubMed Web of Science ®Google Scholar
• Hall EJ. Radio-sensitivity and cell age in the mitotic cycle. Radiobiology for the Radiobiologist. 5th ed. Lippincott Williams & Wilkins, Philadelphia 2000; 51–66
   Google Scholar
• Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316–26
   PubMed Web of Science ®Google Scholar
• Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (“Iressa”). Br J Cancer 2002; 86: 1518–23
   PubMedGoogle Scholar
• Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002; 62: 4307–15
   PubMed Web of Science ®Google Scholar
• Bohling T, Hatva E, Kujala M, Claesson-Welsh L, Alitalo K, Haltia M. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 1996; 55: 522–7
   PubMedGoogle Scholar
• Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993; 4: 121–33
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926–35
   PubMed Web of Science ®Google Scholar
• Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45: 136–9
   PubMed Web of Science ®Google Scholar
• Denekamp J, Hobson B. Endothelial cell proliferation in experimental tumours. Br J Cancer 1982; 46: 711–20
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292–302
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 1. J Clin Oncol 2004; 22: 777–84
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39
   PubMed Web of Science ®Google Scholar